CTIC - CTI BioPharma Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (5Y Monthly) 1.91
52-Week Change 32.56%
S&P500 52-Week Change 320.98%
52 Week High 31.9300
52 Week Low 30.6300
50-Day Moving Average 31.3891
200-Day Moving Average 30.9227

Share Statistics

Avg Vol (3 month) 3449.08k
Avg Vol (10 day) 3305.76k
Shares Outstanding 557.98M
Float 38.29M
% Held by Insiders 10.49%
% Held by Institutions 145.31%
Shares Short (Dec 30, 2019) 4290.49k
Short Ratio (Dec 30, 2019) 40.3
Short % of Float (Dec 30, 2019) 40.60%
Short % of Shares Outstanding (Dec 30, 2019) 40.50%
Shares Short (prior month Nov 28, 2019) 4185.88k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3Jan 02, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin -177.54%
Operating Margin (ttm)-169.46%

Management Effectiveness

Return on Assets (ttm)-24.94%
Return on Equity (ttm)-79.93%

Income Statement

Revenue (ttm)17.45M
Revenue Per Share (ttm)0.30
Quarterly Revenue Growth (yoy)216.60%
Gross Profit (ttm)25.41M
EBITDA -29.02M
Net Income Avi to Common (ttm)-30.99M
Diluted EPS (ttm)-0.5340
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)46.73M
Total Cash Per Share (mrq)0.81
Total Debt (mrq)15.86M
Total Debt/Equity (mrq)60.56
Current Ratio (mrq)1.78
Book Value Per Share (mrq)0.55

Cash Flow Statement

Operating Cash Flow (ttm)-28.98M
Levered Free Cash Flow (ttm)-17.91M